Conference Coverage

Common AEDs confer modestly increased risk of major congenital malformations


 

REPORTING FROM AES 2018

At baseline, all the women had a mean age of about 30 years. Most (75%) were on monotherapy, 20% were on polytherapy, and the rest were not taking an AED. About 60% had focal epilepsy, 31% had generalized epilepsy, and the remainder had an unclassified seizure disorder. Three subjects had multiple seizure types. The most commonly used AEDs were lamotrigine and levetiracetam (both about 30%); 4% were taking zonisamide, 4% carbamazepine, and 4% oxcarbazepine. Topiramate was being used for 2% of the pregnant woman and 5% of the nonpregnant woman. The combination of lamotrigine and levetiracetam was used for 9.0% of pregnant and 5.5% of nonpregnant women, and other polytherapies in 12.0% of the pregnant and 14.0% of the nonpregnant woman. About 4% of the pregnant and 1% of the nonpregnant women were not taking any AED.

There were 10 (2.8%) spontaneous miscarriages among the pregnant women with epilepsy and none among the healthy pregnant women. Spontaneous miscarriages weren’t associated with acute seizures, and there were no major congenital malformations reported among them. There were also two elective abortions among the pregnant women with epilepsy.

There were 18 major congenital malformations among the pregnant woman with epilepsy (5%). A total of 14 were among pregnancies exposed to monotherapy, 3 were in polytherapy-exposed pregnancies, and 1 was in the group not taking any AEDs.

The malformations were:

  • Carbamazepine (one case) – hydronephrosis.
  • Gabapentin (one case) – inguinal hernia.
  • Lamotrigine (five cases) – aortic coarctation, cryptorchidism, hydronephrosis, pectus excavatum, and morning glory syndrome (a funnel-shaped optic nerve disc associated with impaired visual acuity).
  • Levetiracetam (five cases) – atrial septal defect, buried penis syndrome, cryptorchidism, hypoplastic aortic valve, ventricular septal defect.
  • Topiramate (one case) – ventricular septal defect.
  • Zonisamide (one case) – inguinal hernia, absent pinna.
  • Lamotrigine plus clonazepam (one case) – cardiomyopathy.
  • Lamotrigine plus levetiracetam (one case) – microcephaly, myelomeningocele, Chiari II malformation.
  • Levetiracetam plus phenobarbital (one case) – bilateral inguinal hernia.

MONEAD is funded by the National Institutes of Health; Dr. Meador reported no financial disclosures.

SOURCE: Meador KJ et al. AES 2018, Abstract 3.231.

Pages

Recommended Reading

FDA approves Epidiolex for Lennox-Gastaut syndrome and Dravet syndrome
MDedge Pediatrics
Pediatric inpatient seizures treated quickly with new intervention
MDedge Pediatrics
Data support universal adoption of neuroimaging in early-life epilepsy
MDedge Pediatrics
FDA approves Diacomit for Dravet syndrome
MDedge Pediatrics
Epilepsy often accompanies congenital Zika infections
MDedge Pediatrics
DEA moves Epidiolex to schedule V, clearing the way for marketing
MDedge Pediatrics
Oligoclonal bands, initial seizures increase risk of post-ADEM epilepsy in children
MDedge Pediatrics
FDA approves Sympazan for Lennox-Gastaut syndrome
MDedge Pediatrics
OV-101 shows promise for Angelman syndrome
MDedge Pediatrics
Teenagers with epilepsy may benefit from depression screening
MDedge Pediatrics